Prof. Salvatore Oliva discusses the impact of chronic type 2 inflammation on EoE progression, highlighting the need for long-term management.
Experience a pediatric patient's journey from infancy to adolescence with guideline-based learnings on EoE diagnosis, treatment, and long-term care.
Join Prof. Sietze Reitsma for an insightful presentation that will delve into identifying and leveraging key characteristics to optimize patient management and treatment outcomes.
Meet Fernando. Journey through his clinical profile, applying guideline-based checklists to reach a consensus regarding his diagnosis.

Dr. Paller discusses factors influencing AD chronicity and comorbidities, focusing on disease severity, early onset, heredity, multiple allergies, and urban living as important in evaluating AD’s lasting effects on children.
Prof Jean-David Bouaziz describes the multifaceted burden of atopic dermatitis, beyond what can be seen on the skin, at EADV 2025.

Join Sanofi and Regeneron for an educational symposium on type 2 inflammation processes underlying pediatric asthma, atopic dermatitis, and eosinophilic esophagitis.

Join Prof. Kathryn Peterson for an expert review on how different immune cells and inflammatory mediators contribute to the pathogenesis of EoE.

In this video soundbite from the EAACI 2025 symposium, Dr. Zuzana Diamant explains pathophysiological mechanisms underlying asthma and CRSwNP, and how type 2 inflammatory cytokines drive airway remodelling in patients with severe asthma. Additionally, patients with co-existing asthma and CRSwNP have a higher type 2 inflammatory burden than patients with asthma alone.
Learn from Prof. Papadopoulou as she highlights challenges in identifying EoE in pediatric patients and the consequences of delayed diagnosis.

The March 2025 ADVENT symposium in Orlando, Florida brought together 4 dermatology experts to explore the evolving science of type 2 inflammation. Type 2 inflammation plays a central role in the pathophysiology of multiple dermatological diseases, driving chronic immune dysregulation that affects patients with atopic dermatitis (AD) prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP). Understanding the mechanisms behind type 2 inflammation is key to advancing care and improving patient quality of life.